PharmaCorp, which manufactures the drug Aidistan, claims that Aidistan is more effective than the drug Betatol in treating Puma Syndrome. To support its claim, PharmaCorp cites the fact that one of every two victims of Puma Syndrome is treated successfully with Aidistan alone, as opposed to one out of every three treated with Betatol alone. However, PharmaCorp's claim cannot be taken seriously in light of the fact that the presence of Gregg's Syndrome has been known to render Puma Syndrome more resistant to any treatment.
Which of the following, if true, would most support the allegation that PharmaCorp's claim cannot be taken seriously?
a. Among people who suffer from both Puma Syndrome and Gregg's Syndrome, fewer are treated with Aidistan than with Betatol.
b. Among people who suffer from both Puma Syndrome and Gregg's Syndrome, fewer are treated with Betatol than with Aidistan.
c. Gregg's Syndrome reduces Aidistan's effectiveness in treating Puma Syndrome more than Betatol's effectiveness in treating the same syndrome.
d. Betatol is less effective than Aidistan in treating Gregg's Syndrome.
e. Neither Aidistan nor Betatol is effective in treating Gregg's Syndrome.
The correct answer is (A). This argument relies on the assumption that Gregg's Syndrome is more prevalent among Puma Syndrome victims who take Betatol than among those who take Aidistan. (A) essentially affirms this assumption, although it expresses it in a somewhat different way. Given that Gregg's Syndrome renders any Puma Syndrome treatment less effective, if victims who have both syndromes are treated with Betatol while victims who have only Puma Syndrome are treated with Aidistan, then Aidistan will appear to be more effective, although the absence of Gregg's Syndrome might.
My answer was C.
Can somebody tell me how the assumption that Gregg's is more prevalent among Puma victims who take Betatol than among those who take Aidistan is made apparent in the passage? I can't see it.
Which of the following, if true, would most support the allegation that PharmaCorp's claim cannot be taken seriously?
a. Among people who suffer from both Puma Syndrome and Gregg's Syndrome, fewer are treated with Aidistan than with Betatol.
b. Among people who suffer from both Puma Syndrome and Gregg's Syndrome, fewer are treated with Betatol than with Aidistan.
c. Gregg's Syndrome reduces Aidistan's effectiveness in treating Puma Syndrome more than Betatol's effectiveness in treating the same syndrome.
d. Betatol is less effective than Aidistan in treating Gregg's Syndrome.
e. Neither Aidistan nor Betatol is effective in treating Gregg's Syndrome.
The correct answer is (A). This argument relies on the assumption that Gregg's Syndrome is more prevalent among Puma Syndrome victims who take Betatol than among those who take Aidistan. (A) essentially affirms this assumption, although it expresses it in a somewhat different way. Given that Gregg's Syndrome renders any Puma Syndrome treatment less effective, if victims who have both syndromes are treated with Betatol while victims who have only Puma Syndrome are treated with Aidistan, then Aidistan will appear to be more effective, although the absence of Gregg's Syndrome might.
My answer was C.
Can somebody tell me how the assumption that Gregg's is more prevalent among Puma victims who take Betatol than among those who take Aidistan is made apparent in the passage? I can't see it.
